title: Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase.
authors.affiliation: Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.
authors.forename: Shoji
authors.initials: S
authors.lastname: Sanada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Asanuma
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Minamino
authors.forename: Koichi
authors.initials: K
authors.lastname: Node
authors.forename: Seiji
authors.initials: S
authors.lastname: Takashima
authors.forename: Hiroko
authors.initials: H
authors.lastname: Okuda
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Shinozaki
authors.forename: Akiko
authors.initials: A
authors.lastname: Ogai
authors.forename: Masashi
authors.initials: M
authors.lastname: Fujita
authors.forename: Akio
authors.initials: A
authors.lastname: Hirata
authors.forename: Jiyoong
authors.initials: J
authors.lastname: Kim
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Asano
authors.forename: Hidezo
authors.initials: H
authors.lastname: Mori
authors.forename: Hitonobu
authors.initials: H
authors.lastname: Tomoike
authors.forename: Soichiro
authors.initials: S
authors.lastname: Kitamura
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Hori
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kitakaze
mesh_terms: D015720:5'-Nucleotidase / Q000502:physiology*; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002867:Chromones / Q000494:pharmacology; D003327:Coronary Disease / Q000150:complications*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D009025:Morpholines / Q000494:pharmacology; D009203:Myocardial Infarction / Q000209:etiology / Q000473:pathology*; D015428:Myocardial Reperfusion Injury / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D017035:Pravastatin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects*; D013806:Theophylline / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077191:Wortmannin
chemical_list: D015720:5'-Nucleotidase; D000255:Adenosine Triphosphate; D000730:Androstadienes; D002316:Cardiotonic Agents; D002867:Chromones; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009025:Morpholines; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D017035:Pravastatin; D011725:Pyridines; D011804:Quinolines; D013806:Theophylline; D000077191:Wortmannin; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; C031433:8-(4-sulfophenyl)theophylline; C086276:cerivastatin; C108475:pitavastatin; C002630:alpha,beta-methyleneadenosine 5'-triphosphate